SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?

被引：0

作者：

Rudofsky, G. ^{[1
]}

Ruessmann, H. -J.

Siegmund, T. ^{[2
]}

机构：

[1] Univ Klinikum Heidelberg, Abt Innere Med & Klin Chem 1, D-69120 Heidelberg, Germany

[2] Stadt Klinikum Munchen GmbH, Klinikum Bogenhausen, Klin Endokrinol Diabetol & Angiol, Munich, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 22期

关键词：

blood pressure; type; 2; diabetes; weight reduction; glucosuria; drug therapy; Sodium Glucose Linked Transporter (SGLT); INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; DAPAGLIFLOZIN TREATMENT; ADD-ON; TYPE-2; KIDNEY; METFORMIN; CANAGLIFLOZIN; TRANSPORT; WEIGHT;

D O I：

10.1055/s-0032-1333023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since end of 2012 a new therapeutical approach for the treatment of type 2 diabetes is available in Germany. It relies on the modulation of glucose re-absorption in the kidney by inhibition of so called Sodium Glucose Linked Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the kidney in the centre of therapeutical approach of glucose regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying renal mechanisms and to present the advantages and disadvantages of this new therapeutic class. © Georg Thieme Verlag KG, Stuttgart New York.

引用

页码：1172 / 1177

页数：6

共 50 条

[31] SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
Seufert, Jochen
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 543 - 554
[32] SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
Hayashi, Akinori
Takano, Koji
Kawai, Sayuki
Shichiri, Masayoshi
ENDOCRINE JOURNAL, 2016, 63 (02) : 187 - 191
[33] What makes SGLT2 inhibition so effective in lowering blood glucose in diabetes?
Gerasimova, Maria
Rose, Michael
Koepsell, Hermann
Masuda, Takahiro
Mayoux, Eric
Thomson, Scott
Rieg, Timo
Vallon, Volker
FASEB JOURNAL, 2014, 28 (01):
[34] SGLT2 INHIBITION IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES
Guthoff, M.
Mahling, M.
Nadalin, S.
Heyne, N.
TRANSPLANT INTERNATIONAL, 2017, 30 : 32 - 32
[35] LUSEOGLIFLOZIN SGLT2 Inhibitor Treatment of Diabetes
Tiwari, A.
DRUGS OF THE FUTURE, 2012, 37 (09) : 637 - 643
[36] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Mahling, Moritz
Schork, Anja
Nadalin, Silvio
Fritsche, Andreas
Heyne, Nils
Guthoff, Martina
KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (05): : 984 - 992
[37] RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Moura, Filipe
Berg, David
Bellavia, Andrea
Mosenzon, Ofri
Dwyer, Jamie
Scirica, Benjamin M.
Wiviott, Stephen
Bhatt, Deepak L.
Raz, Itamar
Feinberg, Mark William
Morrow, David A.
Sabatine, Marc Steven
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1808 - 1808
[38] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
McGill, Janet B.
DIABETES THERAPY, 2014, 5 (01) : 43 - 63
[39] SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Christoph Wanner
Nikolaus Marx
Diabetologia, 2018, 61 : 2134 - 2139
[40] SGLT2 inhibitor use in the management of feline diabetes mellitus
Cook, Audrey K.
Behrend, Ellen
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2025, 48 : 19 - 30

← 1 2 3 4 5 →